Global Pulmonary Arterial Hypertension Market Size
According to a new market research report published by Global Market Estimates, the Global Pulmonary Arterial Hypertension Market is projected to grow at a CAGR of 5.2% from 2022 to 2027. Congenital heart diseases and other ailments such as HIV infection, chronic liver disease (cirrhosis), and connective tissue disorders (scleroderma, lupus, and others) are fueling market expansion.
Browse 153 Market Data Tables and 113 Figures spread through 185 Pages and in-depth TOC on “Global
Pulmonary
Arterial
Hypertension
Market-
Forecast
to
2027’’
https://www.globalmarketestimates.com/market-report/pulmonary-arterial-hypertension-market-3787
By Drug Class (Endothelin Receptor Antagonists (ERAs), PDE - 5 Inhibitors, Prostacyclin and Prostacyclin Analogs, and SGC Stimulators), By Type (Branded and Generics), By Route of Administration (Oral, Intravenous/ subcutaneous and Inhalational), By Region (North America, Asia Pacific, Central & South America, Europe, and the Middle East & Africa), End-User Landscape Analysis, Company Market Share Analysis, and Competitor Analysis
Key Market Insights • • • • •
As per the type outlook, the generics segment is expected to be the largest segment in the Pulmonary Arterial Hypertension market from 2022 to 2027 The Asia Pacific region is analyzed to be the fastest-growing segment in the market As per the drug class outlook, the prostacyclin and prostacyclin analogs segment is expected to be the largest segment in the Pulmonary Arterial Hypertension market from 2022 to 2027 North America (the United States, Canada, and Mexico) will have a dominant share in the global pulmonary arterial hypertension market from 2022 to 2027 United Therapeutics Corporation, Bayer, Gilead Sciences, Inc., Johnson & Johnson, Viatris Inc., GlaxoSmithKline, Sandoz Inc. (Novartis), Lupin Pharmaceuticals, Inc., Sun Pharmaceutical Industries, Inc., and Teva Pharmaceutical Industries Ltd, among others, are the key players in the pulmonary arterial hypertension market.
Drug Class Outlook (Revenue, USD Billion, 2022-2027) •
Endothelin Receptor Antagonists (ERAs)
•
PDE - 5 Inhibitors
•
Prostacyclin and Prostacyclin Analogs
•
SGC Stimulators
Type Outlook (Revenue, USD Billion, 2022-2027) •
Branded
•
Generics
Route of Administration Outlook (Revenue, USD Billion, 2022-2027) •
Oral
•
Intravenous/ subcutaneous
•
Inhalational
Regional Outlook (Revenue, USD Billion, 2022-2027) North America • • •
The U.S. Canada Mexico
Europe • • • • • •
Germany UK France Spain Italy Rest of Europe
Asia Pacific
• • • • • •
China India Japan South Korea Australia Rest of APAC
Central & South America • •
Brazil Argentina
•
Rest of CSA
Middle East & Africa • • •
Saudi Arabia UAE Rest of MEA
Contact: Yash Jain Email address: yash.jain@globalmarketestimates.com Phone Number: +1 6026667238